CVM - AMEX
CEL-SCI Corporation
$7.17
-6.5%CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
At a Glance
Live Snapshotcvm
Shares Outstanding
Last Annual Value
1.99M
3-Year CAGR
14%
5-Year CAGR
12%
10-Year CAGR
36%
CEL-SCI Corporation Competitors Analysis of shares-outstanding
| Company | shares-outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
CEL-SCI Corporation AMEX:CVM | 1.99M | 10.3% | 8.0% | 26.9% | |
 Aligos Therapeutics, Inc. NASDAQ:ALGS | 9.88M | -26.5% | -24.3% | N/A | |
 INmune Bio, Inc. NASDAQ:INMB | 19.94M | 3.5% | 4.3% | 14.6% | |
 Mersana Therapeutics, Inc. NASDAQ:MRSN | 4.90M | 1.8% | 11.7% | 21.5% | |
 Kezar Life Sciences, Inc. NASDAQ:KZR | 7.32M | -53.5% | -32.6% | -5.6% | |
 PDS Biotechnology Corporation NASDAQ:PDSB | 46.38M | 14.4% | 12.6% | 41.5% | |
 X4 Pharmaceuticals, Inc. NASDAQ:XFOR | 42.29M | 92.5% | 118.0% | 124.1% | |
 OnKure Therapeutics, Inc. NASDAQ:OKUR | 13.52M | 0.4% | 49.4% | N/A |
CEL-SCI Corporation Fair Value Envelope
Related Guides
Continue your CVM research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.